| INTRODUCTION

Chronic hepatitis C virus (HCV) infection is a progressive condition
1 that is the most common cause of cirrhosis, hepatocellular cancer (HCC) and liver disease deaths in the U.S. There are gender-related variations in the epidemiology and clinical course of HCV infection.
For example, men are at least 1.7 times more likely to be infected with HCV than women.
2 Among individuals with chronic HCV, men are also at a higher risk of progression to advanced hepatic fibrosis, cirrhosis and decompensated liver disease than women. [3] [4] [5] Studies suggest that oestrogen hormone may have a protective role against hepatic fibrosis by inhibiting stellate cells, which are responsible for fibrogenesis in the liver. 6, 7 However, this possible biological advantage for women seems to be limited to younger premenopausal women and is attenuated in older and postmenopausal women.
Indeed, postmenopausal women may have a more accelerated progression of fibrosis than men. [8] [9] [10] The prevalence of liver-related sequelae of chronic HCV such as cirrhosis, decompensated liver disease and HCC has been increasing in recent years, 11 in parallel with the ageing of the chronically infected HCV cohort in the US. However, it is unknown if the burden of HCVrelated complications differed between women and men. due to an increase of HCC in women. 12, 13 Similar trends have been seen in several European regions such as France. 5 Combined, these data suggest that the burden of cirrhosis and HCC in HCV-infected women may just be lagging behind that of HCV-infected men.
The US Department of Veterans Affairs (VA) is the largest provider of health care to HCV-infected individuals in the US. VA is also a semiclosed system making long-term studies of incidence and prevalence of HCV complications in large cohorts feasible. Using a national sample of US Veterans with active HCV, including over 5800 women, we examined gender-related differences in the incidence and prevalence of cirrhosis, decompensated cirrhosis and HCC between 2000 and 2013.
| METHODS
| Data source
We used the VA Corporate Data Warehouse (CDW) to identify a cohort of veterans with chronic HCV infection who used one of 129 VA healthcare centres nationwide. CDW includes ICD-9 codes for inpatient and outpatient encounters, results from Alcohol Use Disorders
Identification Test (AUDIT-C) screens, laboratory data, pharmacy data and the Vital Status file which captures death and corresponding date.
| Study design and population
We identified all veterans in the CDW data who had a positive HCV RNA test between January 2000 and December 2013. 
| Study outcomes
| Potential confounders
We examined several confounding variables including date of birth, age at first VA visit, race/ethnicity, diabetes, alcohol use disorder and HIV co-infection. We defined alcohol use disorder by combination of at least two ICD-9 codes and/or positive AUDIT-C screen at least 6 months apart any time during the study follow-up. We relied on ICD-9 codes for diabetes and HIV diagnosis.
We defined yearly time-varying variables indicating years with diagnosed HCV, and for patients with cirrhosis, decompensated cirrhosis and HCC, years with diagnosed cirrhosis, decompensated cirrhosis and HCC, respectively (see analysis section for details). We also defined a time-varying covariate for cumulative inpatient and outpatient visits per year as a surrogate for healthcare utilization.
| Statistical analyses
We examined gender differences in the yearly cumulative incidence and prevalence of cirrhosis, decompensated cirrhosis, HCC and allcause mortality.
For each year, we classified patients with either a new (incident case) or prior diagnosis (prevalent case) of cirrhosis, decompensated cirrhosis or HCC.
| Incidence
We conducted a retrospective cohort study to evaluate the cumulative incidence of each outcome (cirrhosis, decompensated cirrhosis, HCC, death) through discrete-time survival 15 using the pooled logit modelling. 16 We specified a separate model for each of the four outcomes. For each analysis, patients were followed from their index date until the occurrence of the specific study outcome or 31 December Briefly, Joinpoint employs a piecewise linear regression approach to determine whether rates over time are best described by a single line or multiple linear segments (ie, none or ≥1 joinpoints). 21 We allowed a maximum of three joinpoints with a minimum of four linear segments per group. The best joinpoint model (ie, where addition of further joinpoints did not improve model fit) was identified using log-transformed data. 22 We obtained the annual percentage change (APC) in incidence rates over a single linear segment along with 95%
CI for each segment. We also computed the average APC (AAPC) as a weighted average of the APC's from the joinpoint model, with the weights equal to the length of the APC intervals. We compared the trends between two subgroups by employing a test of parallelism using the Monte Carlo permutation test.
| Prevalence analyses
Using a cross-sectional design, we calculated the annual prevalence of each outcome for each year we had full outcomes data (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . For each year, we defined prevalent cirrhosis based on either a new or prior diagnosis of cirrhosis during that particular year. We used the same method to define prevalent decompensated cirrhosis and HCC. We used logistic regression models with fixed effects for year and with cluster robust standard error calculation for multiple observations over time among some patients. 23 The final adjusted models included all other covariates as described above, with the exception of HIV and time-varying covariates for years with known cirrhosis and HCC. We computed mean marginal predictions of prevalence across calendar years for both gender and gender and age subgroups. Last, we evaluated trends in prevalence rates over time using the Joinpoint program as described above. These differences persisted during the 11 years of follow-up. The proportion of patients who received antiviral treatment during study follow-up was not different among men and women (Table 1) . The joinpoint analysis showed that cumulative incidence increased sharply during the initial 3 years of patient follow-up for Table 2) . Despite the between group differences in the incidence rates at any given time point, the trends in the adjusted incidence of cirrhosis were not different in both genders (P-value for test for parallelism=.99).
| RESULTS
| Decompensated cirrhosis
The trends for adjusted incidence rates of decompensated cirrhosis were similar to the trends in cirrhosis. Although the incidence rates of decompensated cirrhosis remained higher in men than in women for all follow-up years, they increased at a similar rate in both groups (AAPC for women=16.9%, 95% CI: 13.9%-19.9%; men=15.6%, 95% CI: 13.0%-18.2%) (P-value for test for parallelism=.97) ( Table 2 ). The cumulative incidence of decompensated cirrhosis was 12.4% (95% CI:
12.1%-12.6%) in women and 18.6% (95% CI: 18.6%-18.7%) in men after 15 years of follow-up.
| Hepatocellular cancer
The incidence rate of HCC after the first year of follow-up was 0.06% (95% CI: 0.06%-0.06%) for women vs 0.3% (95% CI: 0.3%-0.3%) in men ( Figure 1 ). The cumulative incidence rate over the entire study follow-up increased to 1.49% (95% CI: 1.4%-1.5%) in women vs 5.3% (95% CI: 5.3%-5.4%) in men after 15 years of follow-up. The incidence rate of HCC remained low in all patients younger than 45 years at cohort entry. For the remaining patients 45 years and older, HCC incidence was higher in men than in women for most of the follow-up period (Figure 1 ). Joinpoint showed that the greatest increase in the incidence of HCC for both genders was seen in the initial 1-5 years of follow-up (APC for women in year 1-5: 47.0%, 95% CI: 36.3%-59.3%, P<.01; men in year 1-3: 63.4%, 95% CI:
37.0%-95.0%, P<.01). HCC incidence continued to rise albeit more slowly in the later years (APC for women in year 5-15=17.4%, 95% 18.6%-23.4%) for men during the study duration (P-value for test for parallelism=0.72). 
T A B L E 2 Temporal trends in the incidence of HCV-related outcomes among veterans with hepatitis C virus infection by gender
| All-cause mortality
| Prevalence of cirrhosis and related complications
| Cirrhosis
The annual prevalence of cirrhosis was significantly higher in men vs women for all study years. In 2000, 3.2% (95% CI: 3.2%-3.3%) of women vs 4.9% (95% CI: 4.9%-4.9%) of men had been diagnosed with cirrhosis ( Figure 3 ). By 2013, the prevalence for cirrhosis had risen to 13.8% (95% CI: 13.6%-14.1%) and 20.5% (95% CI: 20.4%-20.5%) in women vs men, respectively. Men had consistently higher prevalence of cirrhosis in all three age groups across all study years ( Figure 4) . However, the prevalence of cirrhosis increased at a similar rate in both groups (AAPC in women=11.6%, 95% CI: 10.3%-12.8% and men=12.5%, 95% CI: 11.9%-13.1%) ( 
| Decompensated cirrhosis
Temporal trends in the prevalence of decompensated cirrhosis mirrored those observed for cirrhosis. In 2000, the prevalence of decompensated cirrhosis was 1.6% (95% CI: 1.6%-1.6%) in women and 2.4% (95% CI:
2.4%-2.4%) in men but increased by 2013 to 7.3% (95% CI: 7.2%-7.5%) in women and 11.5% (95% CI: 11.4%-11.5%) in men. The prevalence of decompensated cirrhosis increased at a similar rate in both groups (AAPC in women=11.3%, 95% CI: 10.5%-12.1% and men=10.8%, 95%
CI: 8.8%-12.9%) ( Table 3 ) (P-value for test for parallelism=0.99).
| Hepatocellular cancer
Hepatocellular cancer prevalence was higher in men than in women across all years. Over the study years, HCC prevalence remained 
| DISCUSSION
We found that the incidence and prevalence of HCV complications were higher in men than in women for all study years. However, the rate of increase in the incidence rates of cirrhosis and decompensated cirrhosis among HCV-infected women is similar to the rate of increase in men. Indeed, the AAPC for the incidence of cirrhosis, decompensated cirrhosis and HCC were numerically higher in women than in men, although this difference did not reach statistical significance. We also found that the overall mortality was significantly lower in HCVinfected women than in men ( Figure 1) ; the mortality rate and corresponding 95% CI did not overlap during the entire follow-up. The showed that most of the current and near-term burden in HCV-related cirrhosis was disproportionately attributed to men. However, the trends are expected to change after 2020
24
; with the number of men with cirrhosis declining (due to early maturation of the cohort and competing risks of mortality); whereas the number of women with cirrhosis continuing to increase for at least another decade. Our study is the first to provide direct and contemporary estimates of genderspecific time trends in the burden of cirrhosis and its complications from the largest assembled group of patients with active HCV anywhere in the world-including over 5800 women.
We found an ongoing upward trend in the incidence and prevalence of cirrhosis and decompensated cirrhosis. HCC also increased slightly but to a smaller degree, specifically in women. With cure from HCV now becoming a reality, most of the projected burden of HCV is potentially preventable. However, benefits of HCV treatment are limited only to patients who have been tested, know that they infected with HCV, and have access to affordable treatment. . 33 In a survey of community residents in New South Wales Australia, Grebely et al. 34 found that women with HCV were less likely to receive antiviral treatment than men. Agostini reported similar disparity in a national sample of French patients. 35 In a US study, Charlebois et al. 36 noted a trend towards lower treatment in women who participated in a community-based programme for drug use. Women also undergo liver transplantation at lower rates than men. 37 These and our recent data suggest that the degree of undertreatment may be greater in women than in men and may fuel the rising trends of HCV complications and suboptimal outcomes in women with HCV.
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Our study has several strengths, including the large sample size, long period of follow-up, the use of previously validated definitions for cirrhosis and HCC and examination of demographic and clinical variables that may impact the burden of cirrhosis in HCV. Moreover, most of the patients with HCV in the VA are diagnosed as a result of a system-wide screening program, rather than after development T A B L E 3 Temporal trends in the prevalence of HCV-related outcomes among veterans with hepatitis C virus infection by gender of complications from liver disease. The presence of this unique HCV screening mechanism makes our sample a relatively unbiased cohort.
Finally, the availability of laboratory data allowed us to identify a cohort of patients with confirmed chronic HCV infection.
Our study is limited by the observational retrospective nature of its design. Several unmeasured patient characteristics could have affected our results. Although we had information on antiviral treatment in our database, we opted not to include this variable in our analysis given similar treatment rate in the two study groups and the low efficacy of previous interferon-based treatment used during the study time frame. 39 It is plausible that the rate of increase in HCV complications may decline with the wide dissemination of DAA in the VA and future studies will monitor these trends. Our results were derived from diagnosed HCV-infected patients (men and women) who sought care in the VA healthcare system, and although the generalizability of the biologic process of cirrhosis progression probably extends from these veterans to other HCV-infected individuals in the VA as well as nonveterans, further research would be needed to confirm that. Indeed, there is a high rate of alcohol misuse in women with HCV in the VA (32.9% reported in this study). We were also limited by the sensitivities and specificities of the ICD-9 coding system for our outcomes, which may vary between VA and non-VA practitioners, thus limiting the generalizability of overall rates of cirrhosis and its complications to patients with HCV outside of the VA.
Chronic HCV infection carries high morbidity in women and men alike. HCV-infected women are living longer than men and may further increase their contribution to the burden of HCV-related comorbidities.
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